Miami, November 4, 2025 — SAb Biotherapeutics, Inc. (Nasdaq: SABS) announced that its hATG, SAB-142, is in development for type 1 diabetes (T1D) and other autoimmune diseases.
Four oral presentations and two poster presentations have been accepted for presentation at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD) in Montréal, Canada, November 5-8, 2025. Data highlights the progress of SAB BIO’s lead program, SAB-142, which is in development for delaying the progression of T1D in new onset Stage 3 patients.
Data to be presented includes results from a Phase 1 study showcasing the mechanism of action with sustained immunomodulation of SAB-142, safety data demonstrating a favorable safety profile, and details of a novel pharmacokinetic assay for measuring SAB-142.
“We are making significant progress with the development of SAB-142, and the data we are sharing at this year’s ISPAD annual conference adds to the supporting body of evidence for SAB-142 as a potential best-in-class therapy for the treatment of Stage 3 autoimmune type 1 diabetes,” said Christoph Bausch, Chief Operating Officer, SAB BIO.
Oral presentations include: Specimen quality for multicenter clinical trials: comparing novel blood preservation methods to cryopreserved PBMC, Profiling the Binding Specificities of SAB-142, Immunomodulation Without Sustained Lymphodepletion: SAB-142, and Mechanism of Action of SAB-142.
Poster presentations include: Novel Pharmacokinetic (PK) Assay for Measuring SAB-142 and Safety Profile of SAB-142.
SAB-142 is a disease-modifying immunotherapy in clinical development for autoimmune type 1 diabetes (T1D) with a mechanism of action analogous to that of rabbit ATG (rATG) which can slow disease progression in patients with new or recent onset of Stage 3 T1D. SAB-142, like rATG, directly targets multiple immune cells involved in destroying pancreatic beta cells, and has the potential to preserve insulin-producing beta cells.
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases.
Investor Relations Contact:
Cristi Barnett
ir@sab.bio
Media Contact:
Sheila Carlson
media@sab.bio
Source: SAb Biotherapeutics, Inc.
